www.fdanews.com/articles/142897-inefficacy-kills-late-stage-trial-of-revlimid-in-prostate-cancer

Inefficacy Kills Late-Stage Trial of Revlimid in Prostate Cancer

January 4, 2012

Celgene is stopping a Phase III trial of blockbuster myeloma drug Revlimid to treat castrate-resistant prostate cancer after the formulation failed to show benefit over placebo.
Clinical Trials Advisor